Selective inhibition of XPO1 by selinexor, a small molecule approved for the treatment of relapsed or refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma and currently under clinical development in a variety of hematological and solid tumors [8], has been shown to induce anti-proliferative and anti-tumor activity in experimental models of different tumor types [4], including TNBC cell lines and xenograft models [9,10,11]. Here, XPO1 is linked to neoplasm.